Compare AbbVie Inc (ABBV) vs Akamai Technologies, Inc. (AKAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Akamai Technologies, Inc. — how do they compare? AbbVie Inc trades at $249.84 (market cap $441.94B), while Akamai Technologies, Inc. trades at $116.55 (market cap $16.77B). The key difference: AbbVie Inc is far larger — about 26.4× Akamai Technologies, Inc.'s market cap, and AbbVie Inc pays a 2.77% dividend while Akamai Technologies, Inc. pays none. Which is the better fit depends on your goals.
| ABBV | AKAM | |
|---|---|---|
Market Cap | $441.94B | $16.77B |
Sector | Health | Technology |
52-Week High | $263.58 | $161.14 |
52-Week Low | $197.38 | $71.97 |
Enterprise Value | $506.19B | $22.75B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.
Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Akamai Technologies, Inc.
Akamai operates a content delivery network, or CDN, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,000 points of presence in more than 1,000 cities worldwide. Its customers generally include media companies, which stream video content or make video games available for download, and other enterprises that run interactive or high-traffic websites, such as e-commerce firms and financial institutions. Akamai also has a significant security business, which is integrated with its core web and media businesses to protect its customers from cyberthreats.
Read more on AKAM →
